Avraham Gabay Sells 73,360 Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) CFO Avraham Gabay sold 73,360 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.51, for a total transaction of $330,853.60. Following the transaction, the chief financial officer directly owned 671,785 shares in the company, valued at $3,029,750.35. The trade was a 9.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Oramed Pharmaceuticals Stock Performance

Shares of NASDAQ ORMP opened at $4.60 on Friday. The firm has a market cap of $188.28 million, a P/E ratio of 1.78 and a beta of 1.21. Oramed Pharmaceuticals Inc. has a 1 year low of $1.98 and a 1 year high of $5.19. The firm’s 50 day moving average price is $4.11 and its 200 day moving average price is $3.63.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, June 11th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold”.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Kathmere Capital Management LLC acquired a new stake in shares of Oramed Pharmaceuticals in the first quarter worth approximately $51,000. OMERS ADMINISTRATION Corp acquired a new position in Oramed Pharmaceuticals during the first quarter worth approximately $63,000. Redwood Family Wealth LLC acquired a new position in Oramed Pharmaceuticals during the fourth quarter worth approximately $66,000. XTX Topco Ltd increased its position in Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 14,297 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Oramed Pharmaceuticals during the fourth quarter worth approximately $119,000. 12.73% of the stock is currently owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.